At Manningham Medical Centre, you can find all the data about Lancet Medical Journal Vioxx. We have collected data about general practitioners, medical and surgical specialists, dental, pharmacy and more. Please see the links below for the information you need.


Vioxx, the implosion of Merck, and aftershocks at the FDA - The …

    https://www.thelancet.com/journals/lancet/article/PIIS0140673604175235/fulltext
    The licensing of Vioxx and its continued use in the face of unambiguous evidence of harm have been public-health catastrophes. This controversy will not end …

How Vioxx is changing US drug regulation - The Lancet

    https://www.thelancet.com/journals/lancet/article/PIIS0140673605677124/fulltext
    Merck & Co celebrated victory earlier this month after a New Jersey jury ruled that the company's anti-inflammatory drug rofecoxib (Vioxx) did not cause the heart …

Vioxx: an unequal partnership between safety and efficacy - The …

    https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(04)17198-5/fulltext
    Rofecoxib (Vioxx) is, or was, Merck and Co's leading drug for control of acute pain, and pain associated with osteoarthritis, rheumatoid arthritis, and menstruation. Last …

Discontinuation of Vioxx - The Lancet

    https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(04)17656-3/fulltext
    On Sept 30, 2004, allegedly in response to the results of the APPROVe study, Merck withdrew rofecoxib from the market. Although The Lancetinitially praised Merck's …

Discontinuation of Vioxx - The Lancet

    https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(04)17659-9/fulltext
    Merck has withdrawn rofecoxib (Vioxx) worldwide because, in a placebo-controlled trial for colon cancer progression, its use was associated with an increased …

Discontinuation of Vioxx - The Lancet

    https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(04)17658-7/fulltext
    By contrast with Kim and Reicin's and Jack Nyberg's suggestion, the increased risk of myocardial infarction associated with use of rofecoxib in trials with an external …

Discontinuation of Vioxx - The Lancet

    https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(04)17655-1/fulltext
    The results of Jüni and colleagues' meta-analysis1 seem to make very obvious the case against Vioxx with little room for argument. Unfortunately, the statistical …

What have we learnt from Vioxx? - PMC - National Center for ...

    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1779871/
    The New England Journal of Medicine reported problems with the study in an “expression of concern” published in 2006, w10 and the editor in chief has said that the …

Timeline: The Rise and Fall of Vioxx : NPR - NPR.org

    https://www.npr.org/2007/11/10/5470430/timeline-the-rise-and-fall-of-vioxx
    Merck voluntarily withdrew Vioxx from the market in 2004. Research published in the medical journal Lancet estimates that 88,000 Americans had heart …

Discontinuation of Vioxx - The Lancet

    https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(04)17653-8/fulltext
    Peter Jüni and colleagues1 conclude health authorities should have withdrawn rofecoxib several years before the APPROVe study2 results were made available in …



Need more information about Lancet Medical Journal Vioxx?

At Manningham Medical Centre, we collected data on more than just Lancet Medical Journal Vioxx. There is a lot of other useful information. Visit the related pages or our most popular pages. Also check out our Doctors page.